Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings tomorrow after the bell. Here’s what investors should know.

DexCom met analysts’ revenue expectations last quarter, reporting revenues of $994.2 million, up 2% year on year. It was a mixed quarter for the company, with an impressive beat of analysts’ organic revenue estimates but EPS in line with analysts’ estimates.

Is DexCom a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting DexCom’s revenue to grow 6.7% year on year to $1.10 billion, slowing from the 26.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.50 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. DexCom has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 1.4% on average.

Looking at DexCom’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. ResMed delivered year-on-year revenue growth of 10.3%, beating analysts’ expectations by 1%, and Intuitive Surgical reported revenues up 25.2%, topping estimates by 6.5%. ResMed traded down 8.3% following the results while Intuitive Surgical was also down 4%.

Read our full analysis of ResMed’s results here and Intuitive Surgical’s results here.

Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. DexCom is up 9.9% during the same time and is heading into earnings with an average analyst price target of $97.51 (compared to the current share price of $87.02).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.